Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.

Schönfelder K; Schuh H; Pfister F; Krämer J; Eisenberger U; Skuljec J; Hackert J; Ruck T; Pfeuffer S; Fleischer M; Gäckler A; Hagenacker T; Kribben A; Meuth SG; Kleinschnitz C; Pul R

Abstract

BACKGROUND - OBJECTIVE AND RESULTS - CONCLUSION; Oral cladribine is an approved disease-modifying drug for the treatment of relapsing multiple sclerosis. In controlled clinical trials as well as in post marketing safety assessments, autoimmune conditions have not yet been reported as a specific side effect of cladribine.; Here, we report a case of anti-glomerular basement membrane antibody-mediated glomerulonephritis that occurred shortly after the fourth cladribine treatment cycle.; Neurologists should be attentive to the development of secondary autoimmunity in cladribine-treated patients.